Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

99mTc-rhAnnexin V-128 Imaging of Apoptosis and Cardiotoxicity in Relationship to Ventricular Function in Patients With Early Stage Breast Cancer Receiving Doxorubicin-Based Chemotherapy

NCT02677714 is registered in ClinicalTrials.gov with Advanced Accelerator Applications as lead sponsor.

NCT NCT02677714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02677714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
99mTc-rhAnnexin V-128 Imaging of Apoptosis and Cardiotoxicity in Relationship to Ventricular Function in Patients With Early Stage Breast Cancer Receiving Doxorubicin-Based Chemotherapy
Lead sponsor
Advanced Accelerator Applications
Phase
Phase 2
Overall status
Terminated
Start date
November 2, 2016
Completion date
October 12, 2018
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, doxorubicin induced cardiomyopathy